Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Context and Transition to Occupational Exposure

The legacy context of general health and science information has long served as a foundation for public understanding of medical conditions and therapeutic interventions. Within this broad framework, the relationship between pharmaceutical agents and adverse health outcomes has been a recurring theme, particularly as scientific inquiry has evolved to examine unintended consequences of widely prescribed medications. This heritage provides a necessary backdrop for considering specific exposure scenarios that may arise in occupational settings. Transitioning from this general health perspective, attention now turns to the domain of mass production environments where workers may encounter pharmaceutical compounds during manufacturing processes. The case of bisphosphonate medications, such as Fosamax, illustrates how a drug originally developed for bone health management can become a focus of occupational exposure concern. In production facilities, employees handling these substances may face distinct risks that differ from those of patients taking the medication therapeutically. The scientific evidence connecting Fosamax to osteonecrosis of the jaw has prompted occupational health specialists to examine whether workplace exposure pathways—through inhalation, dermal contact, or accidental ingestion—could pose similar risks to manufacturing personnel. This pivot from general health information to occupational exposure consideration represents a logical extension of the legacy framework, applying established principles of risk assessment to a new population and exposure context.

Bridge Transition: From General Health to Specific Medical Evidence

Building on the legacy framework, we now examine the specific medical evidence linking Fosamax (alendronate sodium) to osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence. However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves pain, swelling, infection, and delayed healing after dental procedures. Diagnosis relies on clinical examination and imaging, often revealing necrotic bone that persists for weeks. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Scientific Evidence Connecting Fosamax to Osteonecrosis of the Jaw

The scientific evidence connecting Fosamax to ONJ is grounded in both clinical reports and mechanistic studies. Clinical data from the FDA label indicate that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Mechanistically, bisphosphonates like alendronate suppress bone turnover by inhibiting osteoclast activity. In the jawbone, which has high remodeling rates due to daily mechanical stress from chewing and dental procedures, this suppression can impair the repair of microdamage and lead to necrosis. Preclinical studies using rat models have shown that bisphosphonate treatment affects jawbone properties, including tissue mineral density distribution and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077/). This multiscale characterization helps explain why the jawbone is particularly vulnerable to bisphosphonate-related complications. Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship, as symptoms correlate with drug exposure and resolve upon discontinuation.

Risk Considerations and Causation for Affected Patients

Risk considerations for affected patients are significant. The adequacy of warnings regarding Fosamax and ONJ is addressed in the FDA-approved labeling. The label explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that long-term use may increase ONJ risk, but the label does not provide specific monitoring protocols for ONJ. Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax use and ONJ onset, excluding other causes such as cancer or radiotherapy, and assessing risk factors like dental procedures. The label notes that in placebo-controlled clinical studies, the percentages of patients with gastrointestinal symptoms were similar in the Fosamax and placebo groups, but ONJ was not systematically studied in these trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Therefore, establishing causation in individual cases requires careful clinical judgment. In summary, the scientific evidence supports a causal link between Fosamax and ONJ, mediated by bisphosphonate-induced suppression of bone turnover in the jaw. The risk is increased with longer exposure and invasive dental procedures. Patients should be informed of this risk and advised to maintain good oral hygiene and undergo dental evaluations before starting therapy. For those who develop ONJ, discontinuation of Fosamax may lead to symptom relief, though recurrence can occur with rechallenge.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

The scientific evidence includes clinical reports from FDA labels showing ONJ in patients taking bisphosphonates like Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), mechanistic studies indicating that bisphosphonates suppress bone turnover in the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/), and temporal patterns where symptoms resolve after drug discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.